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Barrett's esophagusSummary Minichromosomal maintenance (MCM) proteins are participants of DNA replication and may
represent more accurate markers in determining the proliferative fraction within a tumor than proliferative marker
Ki-67. Our study investigated the correlation between MCM4 and MCM7 expression and Ki-67, Bmi1, and cy-
clin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions. MCM4
andMCM7 expression had similar distribution as Ki-67 and Bmi1 expression in esophageal carcinoma and pre-
cancerous lesions. The mean percentage of MCM4,MCM7, and Ki-67 expression increased from squamous ep-
ithelium (5.5%, 7.3%, and 5.9%, respectively), to columnar cell metaplasia (11.2, 13.5%, and 3.4%), Barrett's
esophagus (27.7%, 35.3%, and 8.3%), low-grade dysplasia (42.6%, 52.2%, and 12.9%), high-grade dysplasia
(63.2%, 77.7%, and 29.6%), adenocarcinoma (61.3%, 75.5%, and 24.5%), and squamous cell carcinoma
(74.1, 85.4%, and 36.3%). The percentages of MCM4 and MCM7 expression were signiﬁcantly higher than
Ki-67 expression. Using univariate analysis we found a high percentage ofMCM4 expression (N70%) to be sig-
niﬁcantly associated with lymph node metastasis and shorter survival in the adenocarcinoma group.We also
demonstrated the percentage of MCM4 and MCM7 expression to be signiﬁcantly correlated with Ki-67,
Bmi1, and cyclin E expression in esophageal carcinoma and precancerous lesions. MCM4 and MCM7
may serve as more sensitive proliferative markers for the evaluation of esophageal lesions.
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127MCM4 and MCM7 expression in esophageal carcinoma1. Introduction
The minichromosomal maintenance (MCM) protein family
consists of six related proteins that have essential roles in the ini-
tiation of DNA replication [1]. MCMproteins are also involved
in the elongation of DNA replication and other chromosome
transactions including damage response, transcription, and
chromatin structure [2,3]. Deregulation of the MCM proteins
contributes to cell proliferation and tumorigenesis. Aberrant
expressions of MCM proteins have been reported to be prom-
ising prognostic markers in a number of malignancies [4-17].
It has been claimed thatMCMproteins are potentially more ac-
curate in determining the proliferative fraction within a tumor than
conventional proliferative markers such as Ki-67 [10]. The pres-
ence of MCM2, MCM5, and Ki-67 expression was previously
reported in esophageal squamous dysplasia and Barrett's
esophagus with glandular dysplasia [18,19]. Further, studies
have observedMCM2 expression in esophageal squamous cell car-
cinoma and its positive correlation with Ki-67 expression [18,20].
MCM4 mRNA expression has also been observed in
esophageal squamous cell carcinoma [21]. While limited stud-
ies onMCM4andMCM7expression in esophageal carcinoma have
been reported, none of the studies to the best of our knowledge inves-
tigated MCM4 andMCM7 expression by immunohistochemistry.
Bmi1 is amember of the polycomb-group proteins and functions
as a stem cell marker to regulate the proliferation of progenitor cells
[22]. Our previous study demonstrated that Bmi1 expression
was similar to Ki-67 expression in their distribution in the bas-
al layer of normal squamous epithelium and extending to full thick-
ness in esophageal carcinoma [23]. Cyclin E plays an important
role in promoting G1 cell cycle transition to S-phase [24].
MCM7 has been reported to be the substrate of cyclin E/Cdk2
[25], and high level of MCM4 expression has been associated
with cyclin E expression in non–small cell lung carcinoma
[10]. In addition, we previously found aberrant expression
and ampliﬁcation of cyclin E signiﬁcantly increased in dys-
plastic esophageal lesions [26].
In the current study,weﬁrst examined the immunohistochemical
expressionofMCM4andMCM7 in comparison to the conventional
proliferation marker Ki-67 in esophageal adenocarcinoma, squa-
mous cell carcinoma, and precancerous lesions to determine
the predictive value of these biomarkers for the progression
of esophageal diseases. Next, we investigated the clinicopath-
ologic association ofMCM4,MCM7, and Ki-67 expression in
esophageal adenocarcinoma, squamous cell carcinoma, and
precancerous lesions. We also explored the correlation be-
tween MCM and Bmi1 as well as cyclin E expression.2. Materials and methods
2.1. Construction of tissue microarrays
Tissue microarrays were constructed from representative
areas of formalin-ﬁxed specimens collected from 1997 to2005 in the Department of Pathology and Laboratory
Medicine, University of Rochester Medical Center, Rochester,
NY. The tissue microarrays contained 82 squamous
epithelium, 60 columnar cell metaplasia, 33 Barrett's
esophagus, 38 low-grade dysplasia, 14 high-grade dysplasia,
108 esophageal adenocarcinoma, and 24 esophageal squamous
cell carcinoma. Clinicopathologic data of the patients,
including age, gender, TNM stage, histologic grade, and
duration of survival, were obtained from the medical records.
All patients' identiﬁers were removed. The study was approved
by the institutional review board (Biomarkers of esophageal
carcinoma, RSRB28546).
2.2. Immunohistochemistry
Immunohistochemical studies were performed on 5-μm
thick sections of tissue microarrays. Brieﬂy, after endogenous
peroxidase activity was quenched and nonspeciﬁc bindingwas
blocked, ready-to-use mouse monoclonal antibodies to
MCM4 (1:50; Santa Cruz Biotechnology, Santa Cruz, CA)
and MCM7 (1:50; Santa Cruz Biotechnology) were incubated
at 4°C overnight, and Ki-67 (1:100; Dako, Carpinteria, CA)
was incubated at room temperature for 30 minutes. The sec-
ondary antibody (Flex HRP, Dako) was incubated for 30
minutes. After washing, sections were incubated with Flex
DAB chromogen for 10 minutes and counterstained with Flex
hematoxylin for 5 minutes. Appropriate positive and negative
controls were evaluated. Tissue microarrays were also stained
with hematoxylin and eosin to be used for histologic compar-
ison. The percentage of positive nuclear expression for
MCM4,MCM7, and Ki-67 was reviewed by two pathologists.
Various cut-offs were tested to establish high and low expres-
sion levels. The percentages close to mean expression levels of
MCM4 (70%), MCM7 (70%) and Ki-67 (25%) expression
correlated best with overall survival in esophageal carcinoma.
The cut-offs were set at 70% for MCM4 and MCM7 and at
25% for Ki-67.
Bmi1 and cyclin E immunostaining were performed as pre-
viously described [23,26]. Mouse monoclonal antibodies to
Bmi1 (1:100; Millipore, Bedford, MA) and cyclin E (1:100;
Santa Cruz Biotechnology) were used for immunohistochem-
ical studies.
2.3. Statistical analysis
Pairwise mean comparisons were used to analyze the per-
centages of immunostaining between the histologic groups:
1) adenocarcinoma, high-grade dysplasia, low-grade dyspla-
sia, Barrett's esophagus, and columnar cell metaplasia, and
squamous epithelium; 2) squamous cell carcinoma and squa-
mous epithelium. Pearson's χ2 tests, t tests, and Fisher exact
tests were used as appropriate to assess the association be-
tween clinicopathologic characteristics and MCM4, MCM7,
and Ki-67 expression. Univariate and multivariate regression
models were generated. Probabilities of survival were
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by log-rank test. All statistical tests were 2-sided. A P b .05
was considered to be statistically signiﬁcant. Statistical
analyses were performed using SAS version 9.3 (SAS
Institute, Inc, Cary, NC).3. Results
3.1. Expression and distribution of MCM4 and MCM7
In squamous epithelium, MCM4 and MCM7 expression
were scattered in the basal layer, but more diffusely in the
parabasal or suprabasal layers. While MCM4 and MCM7 ex-
pression were located mainly at the base of glands in columnar
cell metaplasia and Barrett's esophagus, their expression ex-
tended superﬁcially to involve entire glands as the lesions pro-
gressed from dysplasia to adenocarcinoma (Figs. 1 and 2). In
addition,MCM4 andMCM7 expression showedmore reactiv-
ity on the surface of glands compared with the base of glands
in high-grade dysplasia. These distributions of immunostain-
ing were comparable to those of Ki-67 (Fig. 3). All three
immunomarkers demonstrated full-thickness staining in squa-
mous cell carcinoma (Fig. 4).
The mean percentages of MCM4 and MCM7 expression
increased from squamous epithelium (6% and 7%) to colum-
nar cell metaplasia (11% and 14%) and Barrett's esophagus
(28% and 35%). In low-grade dysplasia, the mean percentages
increased to 43% and 52%, respectively. The mean percent-
ages further increased to 63% and 78% in high-grade dysplasiaFig. 1 Immunohistochemical analysis of MCM4 in esophageal adenocarc
cell metaplasia. C, Barrett's esophagus. D, Low-grade dysplasia. E, High-gr
non-dysplastic lesions, MCM4 nuclear staining is distributed in the basal l
cancerous lesions, the glands have full thickness staining for MCM4.and 61% and 76% in adenocarcinoma. The mean percentages
of MCM4 and MCM7 expression were also high in squamous
cell carcinoma (74% and 85%). For Ki-67, the mean percent-
ages of expression were 6% in squamous epithelium, 3% in
columnar cell metaplasia, 8% in Barrett's esophagus, 13% in
low-grade dysplasia, 30% in high-grade dysplasia, 25% in
adenocarcinoma, and 36% in squamous cell carcinoma.
The mean percentages of MCM4 and MCM7 expression are
signiﬁcantly higher than that of Ki-67 expression in all categories
except for squamous epithelium.
Pairwise mean comparisons found the percentages
of MCM4, MCM7, and Ki-67 expression in esophageal
adenocarcinoma and high-grade dysplasia to be signiﬁcantly
greater than those in low-grade dysplasia, Barrett's esophagus,
columnar cell metaplasia, and squamous epithelium (P b .05)
(Table 1). There were also signiﬁcant differences when com-
paring the percentages of MCM4 and MCM7 expression in
(1) low-grade dysplasia with Barrett's esophagus, columnar
cell metaplasia, and squamous epithelium, and (2) Barrett's
esophagus with columnar cell metaplasia and squamous
epithelium. Additionally, the percentages of MCM4, MCM7,
and Ki-67 expression in squamous cell carcinoma were
signiﬁcantly greater than those in squamous epithelium.3.2. Correlations between MCM4, MCM7 and Ki-67
and clinicopathologic features
Correlations between MCM4, MCM7, and Ki-67 expres-
sion and patients' clinicopathologic characteristics, including
age, gender, TNM stage, and histologic grade, were analyzedinoma and precancerous lesions. A, Squamous mucosa. B, Columnar
ade dysplasia. F, Esophageal adenocarcinoma. In normal mucosa and
ayer of the epithelium and lower part of the glands. In dysplastic and
Fig. 2 Immunohistochemical analysis of MCM7 in esophageal adenocarcinoma and precancerous lesions. MCM7 is nuclear stain.
A, Squamous mucosa. B, Columnar cell metaplasia. C, Barrett's esophagus. D, Low-grade dysplasia. E, High-grade dysplasia. F, Esophageal
adenocarcinoma. In normal mucosa and non-dysplastic lesions,MCM7 nuclear staining is distributed in the basal layer of the epithelium and lower
part of the glands. In dysplastic and cancerous lesions, the glands have full thickness staining for MCM7.
129MCM4 and MCM7 expression in esophageal carcinomain the adenocarcinoma group (Table 2) and the squamous
cell carcinoma group (Table 3). Only univariate analysis
identiﬁed a signiﬁcant association between MCM4 expression
and lymph node metastasis in the adenocarcinoma group.
However, multivariate analysis did not yield any signiﬁcant
association.Fig. 3 Immunohistochemical analysis of Ki-67 in esophageal adenocarc
cell metaplasia. C, Barrett's esophagus. D, Low-grade dysplasia. E, High-gr
non-dysplastic lesions, Ki-67 nuclear staining is distributed in the basal laye
cerous lesions, the glands have full thickness staining for Ki-67.3.3. Association of MCM4 and MCM7 with
overall survival
Various cut-offs between high- and low-level expression
were tested. Values close to mean percentages of MCM4
(70%), MCM7 (70%) and Ki-67 (25%) expression had theinoma and precancerous lesions. A, Squamous mucosa. B, Columnar
ade dysplasia. F, Esophageal adenocarcinoma. In normal mucosa and
r of the epithelium and lower part of the glands. In dysplastic and can-
Fig. 4 Immunohistochemical analysis of MCM4, MCM7, and Ki-67 in esophageal squamous cell carcinoma. A, MCM4 in squamous mucosa.
B, MCM4 in esophageal squamous cell carcinoma. C, MCM7 in squamous mucosa. D, MCM7 in esophageal squamous cell carcinoma. E, Ki-67
in squamous mucosa. F, Ki-67 in esophageal squamous cell carcinoma.
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sion and overall survival in esophageal carcinoma. Kaplan–
Meier survival curves to analyze the difference between high
and low expression level for MCM4, MCM7, and Ki-67 were
generated based on overall survival in patients with esophage-
al adenocarcinoma and those with squamous cell carcinoma
(Fig. 5). In the adenocarcinoma group, the overall survival
time for patients with high MCM4 expression level (mean,
27.1 months) was statistically shorter than those with low
MCM4 expression level (mean, 46.5 months) (P = .03). How-
ever, the overall survival time between high (mean, 34.8months) and low (mean, 48.5 months) expression levels for
MCM4 lacked signiﬁcance in the squamous cell carcinoma
group. For MCM7, neither high (mean, 35.8 months) nor
low (mean, 43.9 months) expression levels in the adenocarci-
noma group and neither high (mean, 31.5months) nor low (mean,
65.2 months) expression levels in the squamous cell carcinoma
group demonstrated signiﬁcant difference in overall survival. Similar
ﬁndings were observed for Ki-67 with high (mean, 39.9 months)
and low levels of expression (mean, 37.6months) in the adenocarci-
nomagroup and high (mean, 49.7months) and low levels of expres-
sion (mean, 23.6 months) in the squamous cell carcinoma group.
Table 1 Pairwise mean comparisons of percentages of MCM4, MCM7, and Ki-67 expression between esophageal histologic types
Comparison
Difference in percentage of expression
MCM4 MCM7 Ki-67
Adenocarcinoma High-grade dysplasia −1.9 −2.2 −16.8
Low-grade dysplasia 18.8 ⁎⁎ 23.3 ⁎⁎ 11.6⁎⁎
Barrett's esophagus 33.7 ⁎⁎ 40.2 ⁎⁎ 16.2⁎⁎
Columnar cell metaplasia 50.2 ⁎⁎ 62⁎⁎ 26.3⁎⁎
Squamous epithelium 55.9 ⁎⁎ 68.1 18.6
High-grade dysplasia Low-grade dysplasia 20.6 ⁎⁎ 25.5 ⁎⁎ 16.8⁎⁎
Barrett's esophagus 35.5 ⁎⁎ 42.4 ⁎⁎ 21.3⁎⁎
Columnar cell metaplasia 52⁎⁎ 64.2 ⁎⁎ 26.3⁎⁎
Squamous epithelium 57.8 ⁎⁎ 70.4 ⁎⁎ 23.7⁎⁎
Low-grade dysplasia Barrett's esophagus 14.9 ⁎⁎ 16.9 ⁎⁎ 4.6
Columnar cell metaplasia 31.4 ⁎⁎ 38.7 ⁎⁎ 9.5
Squamous epithelium 37.1 ⁎⁎ 44.9 ⁎⁎ 7 ⁎⁎
Barrett's esophagus Columnar cell metaplasia 16.5 ⁎⁎ 21.8 ⁎⁎ 4.9
Squamous epithelium 22.2 ⁎⁎ 28 ⁎⁎ 2.4
Columnar cell metaplasia Squamous epithelium 5.7 6.2 −2.5
Squamous cell carcinoma Squamous epithelium 68.6 ⁎⁎ 78.1 ⁎⁎ 30.4⁎⁎
⁎⁎ P b .05.
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and cyclin E
All correlations between MCM4, MCM7, and Ki-67
expression, as well as with Bmi1 and cyclin E were positive
and signiﬁcant. All correlation values betweenMCM4,MCM7,
and Ki-67 expression were greater than 0.65 and P b .0001.4. Discussion
The MCM protein family is involved in a number of
essential steps in DNA replication [1]. Their roles in DNA
replication make them candidates as proliferation markers
[8]. In our current study, we compared two members of the
MCM protein family, MCM4 andMCM7, to the conventional
proliferation marker Ki-67, stem cell marker Bmi1, and cell
cycle promoter cyclin E.
The literature on MCM4 and MCM7 expression in esoph-
ageal cancer is limited. Via reverse-transcription polymerase
chain reaction (RT-PCR), MCM4 expression was reported to
be increased in esophageal squamous cell carcinoma when
compared with normal epithelium. MCM4 expression was
also increased in stage T3 carcinoma when compared with
stage T1 carcinoma [27]. By microRNA microarrays and
quantitative RT-PCR, MCM7 mRNA expression and DNA
copy number at the MCM7 locus were found to be up-
regulated and increased in esophageal adenocarcinoma with
disease progression [28]. In cervical cancer, bladder cancer,
cutaneous melanoma, and oral squamous cell carcinoma,
MCM4 and MCM7 have been reported to be promising
prognostic markers for disease progression [4,5,12,14,16].This is the ﬁrst time immunohistochemistry is used to demon-
strate that the percentages of MCM4 and MCM7 expression
signiﬁcantly increased with disease progression and strongly
correlated with Ki-67 expression.
MCM4 and MCM7 expression were scattered in the basal
layer where the stem-like cells are located [29], but more dif-
fusely in the parabasal or suprabasal layers in squamous epi-
thelium. While MCM4 and MCM7 expression were located
mainly at the base of glands in columnar cell metaplasia and
Barrett's esophagus, their expression extended superﬁcially
to involve entire glands as the lesions progressed from dyspla-
sia to adenocarcinoma (Figs. 1 and 2). Similar ﬁndings were
reported in previous studies [18,19]. Two studies on MCM2
andMCM5 in the upper gastrointestinal tract found no expres-
sion on the luminal surface of normal squamous esophagus,
gastric antrum, and duodenum. In addition, MCM2 and
MCM5 expression were observed to gradually extend towards
the surface and upper portion of crypts with increasing degree
of dysplasia [18,19]. Our studies further conﬁrmed that
MCM4 andMCM7 expression had similar distribution as con-
ventional proliferation marker Ki-67 and had signiﬁcant corre-
lation with Ki-67. These ﬁndings suggest that MCM proteins
are potential proliferation markers. In pairwise mean compar-
isons, the percentages of MCM4 and MCM7 expression was
signiﬁcantly greater than the percentages of Ki-67 expression
in esophageal carcinoma and most of the precancerous lesions.
It has been claimed that MCM proteins are more accurate
means of determining the proliferative fraction within a tumor
than conventional proliferation markers, such as Ki-67,
because the latter fails to label cells in the early G1 phase or
is down-regulated early in the differentiation program [10].
The signiﬁcant increase of MCM4 and MCM7 expression
compared with Ki-67 suggests that MCM4 and MCM7 are
Table 2 Clinicopathologic characteristics and percentages of MCM4, MCM7, and Ki-67 expression for esophageal adenocarcinoma group
MCM4 (mean %; SD) P MCM7 (mean %; SD) P Ki-67 (mean %; SD) P
Gender
Male
61.6 (26.6)
n = 97
.71
75.9 (23.5)
n = 94
.81
25 (23)
n = 90
.5
Female
59.1 (26.2)
n = 11
71.8 (27.5)
n = 11
20 (22.5)
n = 10
TNM staging
T
1
55 (21.2)
n = 2
.6
60 (28.3)
n = 2
.64
7.5 (3.5)
n = 2
.36
2
58 (24.3)
n = 15
75 (25.1)
n = 15
19.7 (21.8)
n = 15
3
56.1 (30.7)
n = 23
72.9 (25.3)
n = 21
21.8 (21.7)
n = 20
4
64 (25.7)
n = 68
76.9 (23.4)
n = 67
27.1 (23.7)
n = 63
N
0
50 (27.7)
n = 28
.04 ⁎⁎
68 (27.2)
n = 28
.09
15 (13)
n = 27
.07
1
67.8 (24.1)
n = 54
81.3 (19.9)
n = 53
30.1 (25.5)
n = 49
2
63.3 (21)
n = 15
72.9 (19)
n = 14
21.7 (23.8)
n = 15
3
55.7 (33.2)
n = 11
69 (33.5)
n = 10
27.2 (22.7)
n = 9
Histological grade
Poor
61.4 (26.3)
n = 67
.7
73.8 (24.1)
n = 64
.35
24 (22.3)
n = 63
.81Moderate
61.7 (26.8)
n = 33
78.2 (24.4)
n = 33
25.3 (24.7)
n = 30
Well
51.8 (30.6)
n = 6
71.7 (21.4)
n = 6
17 (15.7)
n = 5
⁎⁎ P b .05.
132 B. Choy et al.potentially more sensitive markers in differentiating various
stages of esophageal disease progression.
Pairwise mean comparisons found the percentages of
MCM4 and MCM7 expression signiﬁcantly increased from
columnar cell metaplasia, Barrett's esophagus, low-grade dys-
plasia to high-grade dysplasia (P b .05), except for squamous
mucosa versus columnar cell metaplasia and esophageal ade-
nocarcinoma versus high-grade dysplasia (Table 1). In addi-
tion, the distribution of MCM4- and MCM7-positive cells
gradually extended from the basal layer to entire glands (Figs. 1
and 2). Our ﬁndings suggest MCM4 and MCM7 proteins are
potentially helpful as proliferation markers in the diagnosis
of challenging cases of dysplasia. However, additional studies
are needed to identify the speciﬁc cut-offs of MCM4 and
MCM7 expression and speciﬁc distribution to differentiate
dysplasia from reactive changes, which is beyond the scope
of the current study.
In a number of malignancies, aberrant expression
of MCM proteins has been associated with poorer prognosis
[5-7,13,17,18,30]. MCM4 was reported to be a promising
marker for distinguishing benign from malignant melanocyticskin lesions and to be associated with shorter survival in pa-
tients with melanoma [30]. In breast cancer, high level of
MCM4 expression was associated with disease progression,
ER-negative or high-grade breast tumors, and shorter survival
[11]. In the gastrointestinal tract,MCM7 expressionwas found
to be a poor prognostic factor for gastric and colorectal cancer
[31,32]. Studies also showed MCM7 expression had poorer
prognosis in lung adenocarcinoma [13,33]. However, the
association between MCM expression and prognosis remains
controversial in other malignancies. One study found that
MCM7 expression was associated with better prognosis in
serous carcinoma of the ovary [15]. Another study reported
no association between MCM4 expression and survival
in non–small cell lung carcinoma [10]. Our analysis demon-
strated that patients with high MCM4 expression level
(N70%) had signiﬁcantly shorter survival in the adenocarcino-
ma group. However, no signiﬁcant difference in survival time
was found in the squamous cell carcinoma group. MCM7 and
Ki-67 expression also showed no signiﬁcant difference in
survival time in both the adenocarcinoma and squamous cell
carcinoma groups.
Table 3 Clinicopathologic characteristics and percentages of MCM4, MCM7, and Ki-67 expression for esophageal squamous cell carcinoma group
MCM4 (mean %;SD) P MCM7 (mean %;SD) P-value Ki-67 (mean %;SD) P
Gender
Male
74.8 (23.5)
n = 14
.84
86.4 (19.8)
n = 14
.59
36.2 (24.6)
n = 13
.93
Female
73 (22.8)
n = 10
84 (19.6)
n = 10
36.5 (29.3)
n = 10
TNM staging
T
1
95 (N/A)
n = 1
.14
100 (N/A)
n = 1
.29
60 (N/A)
n = 1
.71
2
49.2 (37.4)
n = 3
66.7 (30.6)
n = 3
31.7 (27.5)
n = 3
3
50 (N/A)
n = 1
70 (N/A)
n = 1
20 (N/A)
n = 1
4
78.2 (18)
n = 19
88.4 (16.8)
n = 19
36.7 (27.2)
n = 18
N
0
72.8 (34.4)
n = 8
.68
83.8 (27.2)
n = 8
.82
33.8 (27.1)
n = 8
.28
1
72.7 (13.5)
n = 11
84.5 (15.7)
n = 11
41.5 (27.7)
n = 10
2
81.7 (12.6)
n = 3
93.3 (11.5)
n = 3
46.7 (11.5)
n = 3
3
75 (35.4)
n = 2
85 (21.2)
n = 2
5 (7.1)
n = 2
Histological grade
Poor
68.3 (26)
n = 10
.35
82 (20.4)
n = 10
.49
32.2 (29.4)
n = 9
.64
Moderate
76.9 (20.2)
n = 13
86.9 (19.3)
n = 13
37.3 (24.7)
n = 13
Well N/A N/A N/A
Abbreviation: N/A, not applicable.
133MCM4 and MCM7 expression in esophageal carcinomaA previous study ofMCM4 expression in esophageal squa-
mous cell carcinoma found a signiﬁcant association between
increased expression and higher histologic stage [27]. We
did not ﬁnd an association betweenMCM expression and clin-
icopathologic characteristics. Small sample number in the
squamous cell carcinoma group may be a potential reason.
The only signiﬁcant association observed was between
MCM4 expression and lymph node metastasis on univariate
analysis. This association may be related to signiﬁcantly
shorter survival in the esophageal adenocarcinoma group with
high MCM4 expression level (N70%).
MCM4 and MCM7 expression strongly correlated with
Bmi1 and cyclin E expression. Bmi1 is a stem cell marker with
similar distribution to those of MCM4, MCM7, and Ki-67 in
esophageal adenocarcinoma and precancerous lesions [23].
The similar distribution suggests MCM proteins may play an
important role in the proliferation and/or DNA replication of
early progenitor cells [1,28]. Further studies are needed to ex-
plore the underlying mechanism between MCM and Bmi1.
High MCM4 expression level was reported to correlate with
cyclin E expression in non–small cell lung carcinoma by
DNA replication [10]. In addition, budding yeast MCM4 isphosphorylated in vivo during S phase in a manner dependent
on the presence of ﬁve CDK phosphoacceptor residues to trig-
ger DNA replication [34]. Our study further conﬁrmed that
MCM4 expression correlated with cyclin E expression in
esophageal carcinoma. In addition, MCM7 was reported to
be a substrate of cyclin E/CDK2 and can be phosphorylated
on Ser-121 [25]. It has been suggested that phosphorylation
of MCM7 on Ser-121 is involved in preventing DNA replica-
tion, as well as in the regulation of mitotic exit. Our results
showed that MCM7 expression was strongly associated with
cyclin E expression, suggesting that MCM7 may be involved
in the esophageal cell cycle as a substrate of cyclin E/CDK2.
In summary, our ﬁndings demonstrated the percentages of
MCM4 and MCM7 expression signiﬁcantly correlated with
Ki-67, Bmi1, and cyclin E expression in esophageal carcino-
ma and precancerous lesions. MCM4 and MCM7 may serve
as more sensitive proliferation markers for evaluation of
esophageal carcinoma and precancerous lesions. Higher per-
centage of MCM4 expression also showed signiﬁcantly worse
prognosis in patients with esophageal adenocarcinoma and is
associated with lymph node metaplasia, making MCM4 a bet-
ter proliferative marker.
Fig. 5 Kaplan-Meier survival curves for MCM4, MCM7, and Ki-67 in the esophageal adenocarcinoma group (A, B, and C, respectively) and
squamous cell carcinoma group (D, E, and F, respectively). The overall survival time for patients with high percentage of MCM4 expression
(N70%) was statistically shorter than patients with low percentage (≤70%) in the esophageal adenocarcinoma group (P = .03; A), but not in
the squamous cell carcinoma group (D). No statistical signiﬁcance was found inMCM7 and Ki-67 expression in both esophageal adenocarcinoma
(B and C) and squamous cell carcinoma (E and F).
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